Literature DB >> 34306405

Expression and clinical significance of miR-338 and miR-20a in serum of patients with gastric carcinoma.

Min Li1, Jueping Feng1, Chang Gao1, Wen Sun1, Yilian Chen1.   

Abstract

OBJECTIVE: This research intended to explore the content and the role of miR-338 and miR-20a in the serum of patients with gastric carcinoma (GC).
METHODS: Sixty-seven patients with GC, diagnosed and treated for the first time in our hospital from February 2014 to October 2016 were selected as the observation group (OG), and 45 healthy people were selected as the control group (CG). miR-338 and miR-20a of the CG and the OG were tested using qRT-PCR, and the correlation between the two indexes was analyzed by Pearson test. The diagnostic value of miR-338 and miR-20a in GC was analyzed by receiver operating characteristic curve (ROC). The correlation of miR-338 and miR-20a with clinical data was compared, and the correlation of the two with the survival of patients was observed. The independent prognostic factors in patients with GC were analyzed by Cox regression.
RESULTS: miR-338 expression was low in GC patients' serum, while miR-20a was high in GC patients. The expression of the two indexes was negatively correlated (r=-0.609, P<0.001). The areas under the curve of miR-338 and miR-20a were 0.849 and 0.865 respectively. Low expression of miR-338 and high expression of miR-20a were correlated to large tumors, low differentiation degree, high possibility of lymph node metastasis, and late TNM stage of GC patients. Multivariate Cox results revealed that tumor size, lymph node metastasis, differentiation degree, TNM stage, miR-338 and miR-20a were independent prognostic factors.
CONCLUSION: miR-338 and miR-20a are expected to be serological indicators for GC diagnosis and prognosis. AJTR
Copyright © 2021.

Entities:  

Keywords:  clinical significance; expression; gastric carcinoma; miR-20a; miR-338

Year:  2021        PMID: 34306405      PMCID: PMC8290677     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  28 in total

Review 1.  Progress in gastric cancer.

Authors:  Vivian E Strong
Journal:  Updates Surg       Date:  2018-06-05

2.  Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  E C Smyth; M Verheij; W Allum; D Cunningham; A Cervantes; D Arnold
Journal:  Ann Oncol       Date:  2016-09       Impact factor: 32.976

Review 3.  [Current biomarkers for gastric cancer].

Authors:  G B Baretton; D E Aust
Journal:  Pathologe       Date:  2017-03       Impact factor: 1.011

4.  Evaluation of miR-22 and miR-20a as diagnostic biomarkers for gastric cancer.

Authors:  Zahra Jafarzadeh-Samani; Sareh Sohrabi; Khadije Shirmohammadi; Hosein Effatpanah; Reza Yadegarazari; Massoud Saidijam
Journal:  Chin Clin Oncol       Date:  2017-04

Review 5.  Review of recent efforts to discover biomarkers for early detection, monitoring, prognosis, and prediction of treatment responses of patients with gastric cancer.

Authors:  Koichi Sawaki; Mitsuro Kanda; Yasuhiro Kodera
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2018-06-25       Impact factor: 3.869

Review 6.  Progress in the treatment of advanced gastric cancer.

Authors:  Zheyu Song; Yuanyu Wu; Jiebing Yang; Dingquan Yang; Xuedong Fang
Journal:  Tumour Biol       Date:  2017-07

7.  Hypermethylation of miR-338-3p and Impact of its Suppression on Cell Metastasis Through N-Cadherin Accumulation at the Cell -Cell Junction and Degradation of MMP in Gastric Cancer.

Authors:  Bo Guo; Jing Zhang; Qian Li; Zhenghao Zhao; Wenjing Wang; Kaiyue Zhou; Xiaofei Wang; Dongdong Tong; Lingyu Zhao; Juan Yang; Chen Huang
Journal:  Cell Physiol Biochem       Date:  2018-10-11

Review 8.  Gastric cancer: epidemiology, prevention, and therapy.

Authors:  Marino Venerito; Riccardo Vasapolli; Theodoros Rokkas; Peter Malfertheiner
Journal:  Helicobacter       Date:  2018-09       Impact factor: 5.753

Review 9.  The miR-17-92 cluster as a potential biomarker for the early diagnosis of gastric cancer: evidence and literature review.

Authors:  Hong Li; Qiong Wu; Ting Li; Changhao Liu; Lin Xue; Jie Ding; Yongquan Shi; Daiming Fan
Journal:  Oncotarget       Date:  2017-07-11

Review 10.  Gastric Cancer: How Can We Reduce the Incidence of this Disease?

Authors:  Caroline M den Hoed; Ernst J Kuipers
Journal:  Curr Gastroenterol Rep       Date:  2016-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.